Toensberg

• Vi-Siblin for LARS: A randomized, controlled trial. Pending
  2024-514541-11-00 4 Low anterior resection syndrome after low anterior resection for recta
• Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET) Pending
  2025-521330-29-00 4 Major Depression Disorder (MDD)
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending
  2025-523544-12-00 5 Myelodysplastic neoplasms/syndromes (MDS)
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 4 2026-01-08 Newly Diagnosed Multiple Myeloma
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 5 2025-06-15 Ulcerative colitis
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 6 2025-05-26 Recurrent non-muscle invasive bladder cancer
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting
  2024-517606-29-00 5 2020-10-30 Central retinal artery occlusion
• A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in par … Recruiting
  2024-513927-18-00 4 2026-02-16 Amyotrophic Lateral Sclerosis
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• Aminoglycosides in early sepsis Recruiting
  2024-519797-39-00 6 2025-07-01 Sepsis
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27 Follicular lymphoma
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud … Recruiting
  2022-501408-81-01 4 2024-03-04 Covid-19
• The CORTAD study Recruiting
  2024-512888-31-00 11 2023-08-03 Primary adrenal insufficiency (PAI)
• Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy Recruiting
  2024-517854-91-00 5 2019-08-05 Metastatic or high-risk recurrent prostate cancer managed with androge
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten … Ended recruitment
  2023-505514-15-00 5 2022-01-11 Small-cell lung cancer, extensive stage
• PARASTOP - Paracetamol with Strong Opioids Ended
  2024-515012-53-00 5 2021-10-20 Metastatic cancer disease

Showing 1–22 of 22 trials